| scholarly article | Q13442814 |
| P2093 | author name string | Graham Devereux | |
| Jennifer Robertson | |||
| Douglas Fraser-Pitt | |||
| Deborah O'Neil | |||
| Derry Mercer | |||
| Edward Devlin | |||
| P2860 | cites work | Chronic infection with Achromobacter xylosoxidans in cystic fibrosis patients; a retrospective case control study | Q59139143 |
| Antibiotic resistance of bacteria in biofilms | Q28207706 | ||
| Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations | Q28389258 | ||
| Cysteamine (Lynovex®), a novel mucoactive antimicrobial & antibiofilm agent for the treatment of cystic fibrosis. | Q30606113 | ||
| N-acetylcysteine inhibit biofilms produced by Pseudomonas aeruginosa | Q33576307 | ||
| In-vitro activity of antimicrobial agents against Neisseria gonorrhoeae in Brussels | Q33656023 | ||
| Outcome for patients colonised with Burkholderia cepacia in a Birmingham adult cystic fibrosis clinic and the end of an epidemic | Q33775997 | ||
| The changing microbial epidemiology in cystic fibrosis | Q33825634 | ||
| Cysteamine: an old drug with new potential. | Q34328193 | ||
| The chemistry and biological activities of N-acetylcysteine | Q34341263 | ||
| Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis. | Q35536317 | ||
| Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation | Q35852856 | ||
| A randomized controlled crossover trial with delayed-release cysteamine bitartrate in nephropathic cystinosis: effectiveness on white blood cell cystine levels and comparison of safety | Q36067863 | ||
| Activities of moxifloxacin in combination with macrolides against clinical isolates of Mycobacterium abscessus and Mycobacterium massiliense. | Q36086312 | ||
| Patient-reported outcomes in cystic fibrosis | Q36891536 | ||
| Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis | Q37334924 | ||
| Antibiotic treatment of CF lung disease: from bench to bedside | Q37887170 | ||
| The expanding armamentarium of drugs to aid sputum clearance: how should they be used to optimize care? | Q38249201 | ||
| Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study | Q41082564 | ||
| Pantetheinase activity and cysteamine content in cystinotic and normal fibroblasts and leukocytes | Q41636148 | ||
| Nutritional cues control Pseudomonas aeruginosa multicellular behavior in cystic fibrosis sputum | Q42054384 | ||
| Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. | Q51711090 | ||
| Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. | Q52858669 | ||
| P433 | issue | 10 | |
| P921 | main subject | sputum | Q259346 |
| cystic fibrosis | Q178194 | ||
| patient | Q181600 | ||
| emerging pathogen | Q108429945 | ||
| P304 | page(s) | 1507-1512 | |
| P577 | publication date | 2015-08-10 | |
| P1433 | published in | EBioMedicine | Q24912341 |
| P1476 | title | Cysteamine as a Future Intervention in Cystic Fibrosis Against Current and Emerging Pathogens: A Patient-based ex vivo Study Confirming its Antimicrobial and Mucoactive Potential in Sputum | |
| P478 | volume | 2 |
| Q41889486 | A Breathe in Cystic Fibrosis Therapy: A New Therapeutic Endeavor for Cysteamine |
| Q61803810 | Adapting Proteostasis and Autophagy for Controlling the Pathogenesis of Cystic Fibrosis Lung Disease |
| Q37110307 | An Open-Label Investigation of the Pharmacokinetics and Tolerability of Oral Cysteamine in Adults with Cystic Fibrosis |
| Q49733315 | Cigarette Smoke Exposure Inhibits Bacterial Killing via TFEB-Mediated Autophagy Impairment and Resulting Phagocytosis Defect |
| Q37744944 | Cysteamine re-establishes the clearance of Pseudomonas aeruginosa by macrophages bearing the cystic fibrosis-relevant F508del-CFTR mutation |
| Q54247894 | Cysteamine, an Endogenous Aminothiol, and Cystamine, the Disulfide Product of Oxidation, Increase Pseudomonas aeruginosa Sensitivity to Reactive Oxygen and Nitrogen Species and Potentiate Therapeutic Antibiotics against Bacterial Infection. |
| Q38755670 | Efficacy of Rhesus Theta-Defensin-1 in Experimental Models of Pseudomonas aeruginosa Lung Infection and Inflammation |
| Q38722712 | Metabolic interactions between cysteamine and epigallocatechin gallate |
| Q36213831 | N-Acetyl-l-Cysteine and Cysteamine as New Strategies against Mixed Biofilms of Nonencapsulated Streptococcus pneumoniae and Nontypeable Haemophilus influenzae |
| Q38937131 | Nano-based rescue of dysfunctional autophagy in chronic obstructive lung diseases |
| Q42650380 | Strategies for the etiological therapy of cystic fibrosis |
Search more.